PE20151939A1 - 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante - Google Patents
3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutanteInfo
- Publication number
- PE20151939A1 PE20151939A1 PE2015001929A PE2015001929A PE20151939A1 PE 20151939 A1 PE20151939 A1 PE 20151939A1 PE 2015001929 A PE2015001929 A PE 2015001929A PE 2015001929 A PE2015001929 A PE 2015001929A PE 20151939 A1 PE20151939 A1 PE 20151939A1
- Authority
- PE
- Peru
- Prior art keywords
- oxazolidin
- pyrimidin
- onas
- inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se refiere al desarroolo de derivados de 3-pirimidin-4-il-oxazolidin-2-ona de formula (I), o una sal farmaceuticamente aceptable del mismo, en donde R1, R2a, R2b y R3-R7 se definen en la presente. La invencion tambien se refiere a composiciones que contienen un compuesto de la formula (I) y al uso de tales compuestos en la inhibicion de proteinas IDH mutantes que tienen una actividad neomorfica. La invencion se refiere ademas al uso de un compuesto de la formula (I) en el tratamiento de enfermedades o trastornos asociados con tales proteinas IDH mutantes incluyendo pero sin limitar a, trastornos de proliferacion celular como el cancer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361783210P | 2013-03-14 | 2013-03-14 | |
US201361892131P | 2013-10-17 | 2013-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151939A1 true PE20151939A1 (es) | 2016-01-08 |
Family
ID=50382516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001929A PE20151939A1 (es) | 2013-03-14 | 2014-03-12 | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante |
Country Status (29)
Country | Link |
---|---|
US (4) | US9434719B2 (es) |
EP (1) | EP2970240B1 (es) |
JP (1) | JP6387360B2 (es) |
KR (1) | KR20150131224A (es) |
CN (1) | CN105263929B (es) |
AP (1) | AP2015008707A0 (es) |
AR (1) | AR095311A1 (es) |
AU (1) | AU2014229313B2 (es) |
BR (1) | BR112015023412A8 (es) |
CA (1) | CA2903979A1 (es) |
CL (1) | CL2015002472A1 (es) |
CR (1) | CR20150491A (es) |
CU (1) | CU20150119A7 (es) |
DO (1) | DOP2015000240A (es) |
EA (1) | EA028033B1 (es) |
ES (1) | ES2665619T3 (es) |
GE (1) | GEP201706699B (es) |
HK (1) | HK1213251A1 (es) |
IL (1) | IL240972A0 (es) |
MX (1) | MX355945B (es) |
NI (1) | NI201500128A (es) |
PE (1) | PE20151939A1 (es) |
PH (1) | PH12015502018A1 (es) |
SG (1) | SG11201507063YA (es) |
TN (1) | TN2015000392A1 (es) |
TW (1) | TW201444831A (es) |
UY (1) | UY35470A (es) |
WO (1) | WO2014141104A1 (es) |
ZA (1) | ZA201506452B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
MX355945B (es) * | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
EA029052B1 (ru) | 2013-03-14 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с |
CA2922607C (en) | 2013-09-06 | 2022-08-30 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
WO2016038007A1 (en) | 2014-09-12 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Spirocyclic inhibitors of cathepsin c |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
US10449211B2 (en) | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
WO2016142833A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
WO2017019429A1 (en) | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
AU2016348391A1 (en) | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
CN107216312B (zh) * | 2016-03-22 | 2023-08-01 | 上海海和药物研究开发股份有限公司 | 一种具有突变型idh抑制活性的化合物、其制备方法及用途 |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
US10800760B2 (en) | 2017-05-31 | 2020-10-13 | Nantbio, Inc. | Trk inhibition |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
EP3694841A1 (en) | 2017-10-11 | 2020-08-19 | Aurigene Discovery Technologies Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
JP7378394B2 (ja) | 2017-11-03 | 2023-11-13 | オーリジーン オンコロジー リミテッド | Tim-3およびpd-1経路の二重阻害剤 |
EA202090749A1 (ru) | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
CN115448923B (zh) * | 2018-02-13 | 2024-03-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
CN110407855A (zh) * | 2018-04-26 | 2019-11-05 | 上海嗣新生物科技有限公司 | 2-氨基嘧啶啶衍生物及其制备方法和用途 |
CN112469719B (zh) | 2018-05-21 | 2024-01-23 | 内尔维亚诺医疗科学公司 | 杂缩合的吡啶酮化合物及其作为idh抑制剂的用途 |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
CN109659001B (zh) * | 2018-12-18 | 2023-08-04 | 延安大学 | 一种防癌监管系统及方法 |
JP2022519247A (ja) | 2019-02-01 | 2022-03-22 | エフ エム シー コーポレーション | 除草剤としてのジアミノ置換ピリジンおよびピリミジン |
BR112021018704B1 (pt) | 2019-03-19 | 2023-01-10 | Voronoi Inc. | Derivado de heteroarila, método para produção do mesmo, e composição farmacêutica compreendendo a mesma como componente eficaz |
SG11202112158YA (en) * | 2019-05-03 | 2021-12-30 | Praxis Prec Medicines Inc | Kcnt1 inhibitors and methods of use |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
CN110964005A (zh) * | 2019-12-16 | 2020-04-07 | 武汉九州钰民医药科技有限公司 | 一种Alpelisib的制备工艺 |
CN111057051A (zh) * | 2019-12-16 | 2020-04-24 | 武汉九州钰民医药科技有限公司 | PI3K抑制剂Alpelisib的新合成方法 |
CN111362925B (zh) * | 2020-05-26 | 2020-09-08 | 北京鑫开元医药科技有限公司 | 一种4-嘧啶甲酰胺类化合物、药物组合物、制备方法及应用 |
EP4186525A4 (en) | 2020-07-21 | 2024-04-03 | Daiichi Sankyo Co Ltd | COMBINATION DRUG OF TEMOZOLOMIDE AND MUTATED IDH1 ENZYME INHIBITOR |
AR123512A1 (es) * | 2020-09-14 | 2022-12-07 | Totus Medicines Inc | Conjugados terapéuticos |
BR112023024454A2 (pt) * | 2021-06-15 | 2024-02-06 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
JPS4921149B1 (es) | 1970-12-28 | 1974-05-30 | ||
JPS4921148B1 (es) | 1970-12-28 | 1974-05-30 | ||
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
WO1992000970A1 (fr) | 1990-07-03 | 1992-01-23 | Mitsui Petrochemical Industries, Limited | Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose |
KR100275300B1 (ko) | 1995-04-13 | 2000-12-15 | 고바야시 유키오 | 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof) |
JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
DK1020462T3 (da) | 1997-07-24 | 2004-04-26 | Zenyaku Kogyo Kk | Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
DE69906397T2 (de) | 1998-01-16 | 2004-02-19 | F. Hoffmann-La Roche Ag | Benzosulfonderivate |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US6489344B1 (en) | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
JP2002535318A (ja) | 1999-01-22 | 2002-10-22 | アムジエン・インコーポレーテツド | キナーゼ阻害薬 |
ATE253915T1 (de) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
JP2003503354A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Srcキナーゼ阻害剤化合物 |
AU6605200A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
WO2001005783A1 (en) | 1999-07-15 | 2001-01-25 | Pharmacopeia, Inc. | Bradykinin b1 receptor antagonists |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
CN1429222A (zh) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
CN100355751C (zh) | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2-取代的4-杂芳基-嘧啶、其组合物及其用途 |
AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
AU4114201A (en) | 2000-04-28 | 2001-11-12 | Tanabe Seiyaku Co | Cyclic compounds |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
CA2422367C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
KR100947185B1 (ko) | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
DE60314603T2 (de) | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | Zusammensetzungen brauchbar als protein-kinase-inhibitoren |
ATE466580T1 (de) | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
WO2004000820A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
EP1546115A4 (en) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | SUBSTITUTED PYRIMIDINES |
JP2006515274A (ja) | 2002-10-08 | 2006-05-25 | マサチューセッツ・インスティテュート・オブ・テクノロジー | コレステロール輸送の調節のための化合物 |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
CA2507100C (en) | 2002-11-21 | 2012-10-09 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
CA2519677A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US7763627B2 (en) | 2003-04-09 | 2010-07-27 | Exelixis, Inc. | Tie-2 modulators and methods of use |
JP2007523875A (ja) | 2003-07-15 | 2007-08-23 | ニューロジェン・コーポレーション | バニロイド受容体リガンドとしての置換ピリミジン−4−イルアミン類縁体 |
AU2004257289A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
WO2005099711A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
AU2005317176A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
CN101080401A (zh) | 2004-12-13 | 2007-11-28 | 神经能质公司 | 经取代的二芳基类似物 |
EP1836169B9 (en) | 2004-12-28 | 2012-07-04 | Kinex Pharmaceuticals, LLC | Compositions and methods of treating cell proliferation disorders |
CA2595205A1 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
CA2599320A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
WO2006113704A2 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
AU2007207481B2 (en) | 2006-01-20 | 2012-08-23 | Merck Sharp & Dohme Corp. | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
PE20070854A1 (es) | 2006-01-20 | 2007-09-10 | Schering Corp | Compuestos heterociclos como agonistas del receptor de acido nicotinico |
JP2009524616A (ja) | 2006-01-27 | 2009-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | Cns疾患のための4−イミダゾール誘導体の使用 |
CL2007003847A1 (es) | 2006-12-28 | 2008-04-18 | Basf Ag | Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer. |
US8173647B2 (en) | 2007-02-06 | 2012-05-08 | Gordana Atallah | PI 3-kinase inhibitors and methods of their use |
US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
WO2009109605A1 (en) | 2008-03-05 | 2009-09-11 | Novartis Ag | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
AU2009228797B2 (en) | 2008-03-26 | 2012-07-19 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes |
EP2276750A2 (en) | 2008-03-27 | 2011-01-26 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
US8575338B2 (en) | 2008-04-09 | 2013-11-05 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers |
GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
CA2736361C (en) | 2008-10-31 | 2017-10-10 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
EP2394999B1 (en) | 2009-02-06 | 2014-01-29 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
WO2010105243A1 (en) | 2009-03-13 | 2010-09-16 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
PL2432767T3 (pl) | 2009-05-19 | 2013-11-29 | Dow Agrosciences Llc | Związki i sposoby zwalczania grzybów |
TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
SG179085A1 (en) | 2009-09-09 | 2012-04-27 | Avila Therapeutics Inc | Pi3 kinase inhibitors and uses thereof |
US20120215788A1 (en) | 2009-11-18 | 2012-08-23 | Nokia Corporation | Data Processing |
WO2011072174A1 (en) * | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US20130109643A1 (en) * | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
EP2593425B1 (en) * | 2010-07-16 | 2018-10-17 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their method of use |
WO2012044727A2 (en) | 2010-10-01 | 2012-04-05 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
MX337179B (es) | 2010-10-18 | 2016-02-15 | Cerenis Therapeutics Holding Sa | Compuestos, composiciones y metodos utiles para la movilizacion de colesterol. |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
JP2014505107A (ja) | 2011-02-11 | 2014-02-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 過誤腫性腫瘍細胞を阻害する方法 |
CN102827073A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN103764130A (zh) | 2011-09-01 | 2014-04-30 | 诺华股份有限公司 | 用于治疗骨癌或者预防原发性癌细胞转移性播散入骨中的pi3k抑制剂 |
KR20140069235A (ko) | 2011-09-27 | 2014-06-09 | 노파르티스 아게 | 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
WO2013052395A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
CN108553467A (zh) | 2012-04-02 | 2018-09-21 | 赛特凯恩蒂克公司 | 改善膈肌功能的方法 |
KR102163931B1 (ko) | 2012-04-11 | 2020-10-12 | 싸이토키네틱스, 인코포레이티드 | 골격근 피로에 대한 저항을 개선 |
RU2630975C2 (ru) | 2012-05-16 | 2017-09-15 | Новартис Аг | Режим дозирования pi-3 киназы |
RU2014150494A (ru) | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Пирролидиногетероциклы |
RU2014154009A (ru) | 2012-06-06 | 2016-08-10 | Новартис Аг | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания |
RU2705095C2 (ru) | 2012-08-16 | 2019-11-05 | Новартис Аг | Комбинация ингибитора pik3 и ингибитора с-мет |
RU2646760C2 (ru) | 2012-10-23 | 2018-03-07 | Новартис Аг | Усовершенствованный способ получения 5-(2,6-ди-4-морфолинил-4-пиримидинил)-4-трифторметилпиридин-2-амина |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
DK3007689T3 (en) | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2014
- 2014-03-12 MX MX2015012552A patent/MX355945B/es active IP Right Grant
- 2014-03-12 AP AP2015008707A patent/AP2015008707A0/xx unknown
- 2014-03-12 ES ES14712785.6T patent/ES2665619T3/es active Active
- 2014-03-12 AU AU2014229313A patent/AU2014229313B2/en not_active Ceased
- 2014-03-12 CN CN201480027484.7A patent/CN105263929B/zh active Active
- 2014-03-12 CA CA2903979A patent/CA2903979A1/en not_active Abandoned
- 2014-03-12 KR KR1020157028897A patent/KR20150131224A/ko not_active Application Discontinuation
- 2014-03-12 EP EP14712785.6A patent/EP2970240B1/en active Active
- 2014-03-12 JP JP2015562496A patent/JP6387360B2/ja active Active
- 2014-03-12 WO PCT/IB2014/059695 patent/WO2014141104A1/en active Application Filing
- 2014-03-12 PE PE2015001929A patent/PE20151939A1/es not_active Application Discontinuation
- 2014-03-12 SG SG11201507063YA patent/SG11201507063YA/en unknown
- 2014-03-12 GE GEAP201413934A patent/GEP201706699B/en unknown
- 2014-03-12 US US14/408,418 patent/US9434719B2/en active Active
- 2014-03-12 BR BR112015023412A patent/BR112015023412A8/pt not_active Application Discontinuation
- 2014-03-12 EA EA201591745A patent/EA028033B1/ru not_active IP Right Cessation
- 2014-03-13 TW TW103109158A patent/TW201444831A/zh unknown
- 2014-03-13 US US14/208,015 patent/US20140275083A1/en not_active Abandoned
- 2014-03-14 AR ARP140101012A patent/AR095311A1/es unknown
- 2014-03-14 UY UY0001035470A patent/UY35470A/es not_active Application Discontinuation
-
2015
- 2015-08-31 IL IL240972A patent/IL240972A0/en unknown
- 2015-09-02 ZA ZA2015/06452A patent/ZA201506452B/en unknown
- 2015-09-04 CL CL2015002472A patent/CL2015002472A1/es unknown
- 2015-09-04 TN TN2015000392A patent/TN2015000392A1/en unknown
- 2015-09-09 NI NI201500128A patent/NI201500128A/es unknown
- 2015-09-09 PH PH12015502018A patent/PH12015502018A1/en unknown
- 2015-09-14 DO DO2015000240A patent/DOP2015000240A/es unknown
- 2015-09-14 CR CR20150491A patent/CR20150491A/es unknown
- 2015-09-14 CU CUP2015000119A patent/CU20150119A7/es unknown
-
2016
- 2016-02-01 HK HK16101122.1A patent/HK1213251A1/zh unknown
- 2016-07-13 US US15/209,731 patent/US9688672B2/en active Active
-
2017
- 2017-04-27 US US15/499,824 patent/US10112931B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151939A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
NI201400026A (es) | 3 - pirimidin - 4 - il - oxazolidin - 2 - onas como inhibidores de la idh mutante. | |
MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
CR20160035A (es) | Inhibidores de bromodominios | |
EA202090291A2 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201491356A1 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
EA201490357A1 (ru) | Индазолы | |
DOP2013000084A (es) | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap) | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
IN2015DN01156A (es) | ||
MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
EA201490846A1 (ru) | Новые производные арилхинолина | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
EA201590656A1 (ru) | Азаиндолины | |
UY30514A1 (es) | Compuestos organicos | |
UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |